

5. [Delete] In combination with claims 1 through 4 and bromine acetamido benzoyl ethyl acetate: Compounds that have therapeutic potential in cancer treatment.
6. [Delete] In combination with claims 1 through 4 and bromine acetamido benzoyl ethyl acetate: Compounds that may have therapeutic potential in treating other diseases such as fungal and parasitic infections or malaria.
7. [Delete] In combination with claims 1 through 4 and bromine acetamido benzoyl ethyl acetate: Compounds that may have therapeutic potential in treating other indications such as gout, restenosis, multiple sclerosis, Parkinson's and Alzheimer's diseases.

We request that Claim 3 is deleted and the following Claims added to replace it:

NEW Claim 8: A tubulin ligand that causes a G1/S-phase arrest.

NEW Claim 9: A tubulin ligand according to Claim 8, where the iodo-acetamido benzoyl ethyl acetate is the specie.

NEW Claim 10: The medicinal drug of Claim 9 wherein it causes tumor volume reduction of prostate cancer in a model organism.

NEW Claim 11: The medicinal drug of Claim 9 wherein it cures prostate cancer in 20% of cases in a model organism.

NEW Claim 12: The medicinal drug of Claim 9 wherein it causes selective cell death of T-cell Leukemia cancer cells.

NEW Claim 13: The medicinal drug of Claim 9 wherein it causes selective cell death of Myelodysplasia syndromes cell types.

NEW Claim 14: The medicinal drug of Claim 9 wherein it causes selective cell death of Melanoma cells.

NEW Claim 15: The medicinal drug of Claim 9 wherein it has anti-cancer activity.

NEW Claim 16: The medicinal drug of Claim 9 wherein it causes selective cell death of Renal Cancer cells.

NEW Claim 17: The medicinal drug of Claim 9 wherein it causes selective cell death of Breast Cancer cells.

NEW Claim 18: The medicinal drug of Claim 9 wherein it causes selective cell death of Non-small Cell Lung Cancer cells.

NEW Claim 19: The medicinal drug of Claim 9 wherein it causes selective cell death of Colon Cancer cells.

NEW Claim 20: The medicinal drug of Claim 9 wherein it causes selective cell death of lymphoma wild type cancer cells.

NEW Claim 21: The medicinal drug of Claim 9 wherein it causes selective cell death of lymphoma MDR negative cancer cells.

NEW Claim 22: The medicinal drug of Claim 9 wherein it does not cause cell death of normal lymphocytes when added to a culture of these cells at the ID90 dose of lymphoma.

NEW Claim 23: A situation where the G1/S phase arrest could be used as a tool to develop tubulin ligands with anti-cancer properties.

Amended Claim 4 – A tubulin ligand that causes a biphasic phosphorylation of bcl-2, one phase being between 1-3h and the next phase being 12h onwards.

NEW Claim 24 – A situation where the 1-3h Bcl2 phosphorylation phase could be used as a tool to develop tubulin ligands with anti-cancer properties.



AS Davis
Cytoskeleton Inc.